Development of antibiotic resistance during simulated treatment of Pseudomonas aeruginosa in chemostats

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Feng, Yanfang ^a   Hodiamont, Caspar J ^b   Van Hest, Reinier M ^b   Brul, Stanley ^a   Schultsz, Constance ^b,c   Ter Kuile, Benno H ^a,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d Food and Consumer Product Safety Authority   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CEFTAZIDIME; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

AMPD GENE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CHEMOSTAT; DACB GENE; GENE MUTATION; HFQ GENE; IN VITRO STUDY; MEXB GENE; MEXR GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPRD GENE; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; SURVIVAL RATE; YERD GENE; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEFTAZIDIME; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 84960533298     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149310     Document Type: Article

References (35)

1. Brusselaers N, Vogelaers D, Blot S (2011) The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 1:47. doi: 10.1186/2110-5820-1-47 PMID: 22112929
2. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, et al. (2010) Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 38:1045-1053. doi: 10.1097/CCM. 0b013e3181cc4824 PMID: 20048677
3. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742-2751. PMID: 14668610
4. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596. PMID: 16625125
5. Toprak E, Veres A, Michel JB, Chait R, Hartl DL, Kishony R (2012) Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat Genet 44:101-105.
6. van der Horst MA, Schuurmans JM, Smid MC, Koenders BB, Ter Kuile BH (2011) De Novo Acquisition of Resistance to Three Antibiotics by Escherichia coli. Microb Drug Resist 17:141-147. doi: 10.1089/mdr.2010.0101 PMID: 21235391
7. Drlica K, Zhao X (2007) Mutant selection window hypothesis updated. Clin Infect Dis 44:681-688. PMID: 17278059
8. Handel N, Schuurmans JM, Brul S, Ter Kuile BH (2013) Compensation of the Metabolic Costs of Antibiotic Resistance by Physiological Adaptation in Escherichia coli. Antimicrob Agents Chemother 57:3752-3762. doi: 10.1128/AAC.02096-12 PMID: 23716056
9. Handel N, Schuurmans JM, Feng Y, Brul S, Ter Kuile BH (2014) Interaction between Mutations and Regulation of Gene Expression during Development of De Novo Antibiotic Resistance. Antimicrob Agents Chemother 58:4371-4379. doi: 10.1128/AAC.02892-14 PMID: 24841263
10. Fish DN, Ohlinger MJ (2006) Antimicrobial resistance: factors and outcomes. Crit Care Clin 22:291-311, vii. PMID: 16678001
11. Roberts JA, Kruger P, Paterson DL, Lipman J (2008) Antibiotic resistance-what's dosing got to do with it? Crit Care Med 36:2433-2440. doi: 10.1097/CCM.0b013e318180fe62 PMID: 18596628
12. Blot S, Vandewoude K, Hoste E, Colardyn F (2003) Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa. J Hosp Infect 53:18-24. PMID: 12495681
13. Benko AS, Cappelletty DM, Kruse JA, Rybak MJ (1996) Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 40:691-695. PMID: 8851594
14. Delattre IK, Musuamba FT, Jacqmin P, Taccone FS, Laterre PF, Verbeeck RK, et al. (2012) Population pharmacokinetics of four beta-lactams in critically ill septic patients comedicated with amikacin. Clin Biochem 45:780-786. doi: 10.1016/j.clinbiochem.2012.03.030 PMID: 22503878
15. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM (2010) Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 65:1073-1075. doi: 10.1093/jac/dkq044 PMID: 20176578
16. Smith SV, Gould IM (2004) Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance. Expert Rev Anti Infect Ther 2:227-234. PMID: 15482188
17. Schuurmans JM, Nuri Hayali AS, Koenders BB, ter Kuile BH (2009) Variations in MIC value caused by differences in experimental protocol. J Microbiol Methods 79:44-47. doi: 10.1016/j.mimet.2009.07. 017 PMID: 19635505
18. Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B (2007) Development of resistance in wildtype and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother 51:3642-3649. PMID: 17682103
19. Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, et al. (2012) Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 56:1680-1685. doi: 10.1128/AAC.05693-11 PMID: 22232279
20. Melnyk AH, Wong A, Kassen R (2015) The fitness costs of antibiotic resistance mutations. Evol Appl 8:273-283. doi: 10.1111/eva.12196 PMID: 25861385
21. Feng Y, Händel N, de Groot M, Brul S, Schultsz C, ter Kuile B (2014) Experimental Simulation of the Effects of an Initial Antibiotic Treatment on a Subsequent Treatment after Initial Therapy Failure. Antibiotics 3:49.
22. Kollef MH (2001) Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 5:189-195. PMID: 11511331
23. Sanchez-Romero MA, Casadesus J (2014) Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proc Natl Acad Sci U S A 111:355-360. doi: 10.1073/pnas.1316084111 PMID: 24351930
24. Lee HH, Molla MN, Cantor CR, Collins JJ (2010) Bacterial charity work leads to population-wide resistance. Nature 467:82-85. doi: 10.1038/nature09354 PMID: 20811456
25. Vega NM, Gore J (2014) Collective antibiotic resistance: mechanisms and implications. Curr Opin Microbiol 21:28-34. doi: 10.1016/j.mib.2014.09.003 PMID: 25271119
26. Bos J, Zhang Q, Vyawahare S, Rogers E, Rosenberg SM, Austin RH (2015) Emergence of antibiotic resistance from multinucleated bacterial filaments. Proc Natl Acad Sci U S A 112:178-183. doi: 10. 1073/pnas.1420702111 PMID: 25492931
27. Justice SS, Hunstad DA, Cegelski L, Hultgren SJ (2008) Morphological plasticity as a bacterial survival strategy. Nat Rev Microbiol 6:162-168. PMID: 18157153
28. Fernandez L, Breidenstein EB, Hancock RE (2011) Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat 14:1-21. doi: 10.1016/j.drup. 2011.01.001 PMID: 21288762
29. Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A (2001) Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 3:23-35. PMID: 11226851
30. Jin L, Li J, Nation RL, Nicolazzo JA (2012) Effect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice. Antimicrob Agents Chemother 56:5240-5246. doi: 10. 1128/AAC.00713-12 PMID: 22850514
31. Martinez JL, Baquero F (2000) Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44:1771-1777. PMID: 10858329
32. Mogre A, Sengupta T, Veetil RT, Ravi P, Seshasayee AS (2014) Genomic analysis reveals distinct concentration-dependent evolutionary trajectories for antibiotic resistance in Escherichia coli. DNA Res 21:711-726. doi: 10.1093/dnares/dsu032 PMID: 25281544
33. Oz T, Guvenek A, Yildiz S, Karaboga E, Tamer YT, Mumcuyan N, et al. (2014) Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol Biol Evol 31:2387-2401. doi: 10.1093/molbev/msu191 PMID: 24962091
34. Andersson DI (2006) The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9:461-465. PMID: 16890008
35. Coward C, Restif O, Dybowski R, Grant AJ, Maskell DJ, Mastroeni P (2014) The effects of vaccination and immunity on bacterial infection dynamics in vivo. PLoS Pathog 10:e1004359. doi: 10.1371/journal.ppat.1004359 PMID: 25233077